Insilico says its AI-designed lung drug lowered biological age markers in a 42-patient trial
THE SO WHAT
An AI-designed lung drug that makes patients look biologically younger across six independent aging clocks is an early but concrete datapoint that AI can touch not just disease but systemic aging markers. Biotech and pharma teams should be reassessing where in their pipelines AI-first discovery could justify new trials, even at small initial scales.
READ THE SOURCE
MORE FROM THE WIRE
Deep & Emerging TechStop buying security tools: start buying a system
Security is converging toward continuous, integrated systems rather than point tools with pretty dashboards. CISOs should be rationalizing vendors around data flow, validation, and response automation, not just “consolidation” for its own sake.
Deep & Emerging TechCyber confidence must be tested, never assumed
Purple teaming is moving from “nice-to-have exercise” to the only credible way to validate that your controls work against real attackers. If your board is hearing cyber risk updates without red/blue test results, they’re getting a theory, not a status.
Deep & Emerging Tech'It's extremely creepy': LG TVs collect far more data on you than you'd expect, says new report, including logging microphone audio while on standby and detecting your wireless devices including phones and smartwatches — and users are furious
Smart TVs quietly acting as network sensors and microphones turn every living room and office into a data collection surface. Enterprises should treat consumer-grade displays on corporate networks as untrusted endpoints and segment accordingly.
Deep & Emerging TechRansomware hackers dump 1.4 million stolen records from German government
A 1.4 million-record dump from a government system is another reminder that state-grade targets are not uniquely vulnerable—any large data holder is in scope. If you manage citizen or customer identity data, assume breach and invest in blast-radius reduction, not just perimeter hardening.